Location

Interleukin-34 as a marker for subclinical proliferative lupus nephritis (LN).
Serum IL-34 may be used as a surrogate marker for early renal affection in silent LN, especially the proliferative type. Sage Journals, Lupus, 04/01/2020. (Also see Symptoms and Complications of Lupus and Interleukins)
This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.

Cantargia Selects CAN10 as Development Project in Systemic Sclerosis and Myocarditis.
Cantargia develops antibody-based pharmaceuticals against the interleukin 1 receptor accessory protein (IL1RAP) and the project will focus on unmet medical need in systemic sclerosis and myocarditis. PR Newswire, 12/05/2019. (Also see Interleukins)
This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.

The Roles of IL-1 Family Cytokines in the Pathogenesis of Systemic Sclerosis (SSc).
Here, we aim to give a brief overview of IL-1 family cytokines and discuss their pivotal roles in the pathogenesis of SSc. PubMed, Front Immunol, 2019 Sep 13;10:2025. (Also see Interleukins)
This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.

IL-16 expression is increased in the skin and sera of patients with systemic sclerosis.
The regional up-regulation of IL-16 in the skin is not only associated with skin sclerosis, but also with systemic IL-16 activation. PubMed, Rheumatology (Oxford), 08/03/2019. (Also see Skin Fibrosis and Interleukins)
This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.

Serum concentrations of IL-17A, IL-17B, IL-17E and IL-17F in patients with systemic sclerosis (SSc).
Increased synthesis of IL-17B, IL-17E and IL-17F appears to play a role in the pathogenesis of SSc, in contrast to IL-17A. PubMed, Arch Med Sci, 2019 May;15(3):706-712. (Also see Interleukins)
This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.

Interleukin-17 pathways in systemic sclerosis–associated fibrosis.
There is multitude of evidence from across different tissues that interleukin-17 (IL-17) and its downstream pathways are strongly associated with the initiation and propagation of fibrosis. PubMed, Rheumatol Int, 05/09/2019. (Also see Interleukins and Skin Fibrosis)
This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.

Soluble TNF-R1, VEGF and other cytokines as markers of disease activity in systemic lupus erythematosus (SLE) and lupus nephritis (LN).
These results indicate that for active LN, sTNF-R1 could be a useful serum cytokine marker, with potential for vascular endothelial growth factor in the urine. PubMed, Lupus, 2019 May 2:961203319845487. (Also see Diagnosis of Lupus and Interleukins)
This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.

Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis (SSc).
The profound impact of IL-6R blockade on the activated fibroblast phenotype highlights the potential of IL-6 as a therapeutic target in SSc and other fibrotic diseases. PubMed, Ann rheumatologist Dis, 05/31/2018. (Also see Interleukins and Clinical Trials)
This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.

The IL-1 family of cytokines. Do they have a role in scleroderma fibrosis?
Recent analyses of the IL-1 family of cytokines have demonstrated that many of them play a role in skin inflammation and fibrosis and their corresponding antagonists (IL-1RA and IL-36RA) can abrogate this pathology. PubMed, Immunol Lett, 12/04/2017. (Also see Interleukins)
This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.

The combination of IL-6 and its soluble receptor is associated with the response of rheumatoid arthritis (RA) patients to tocilizumab.
RA patients could be easily stratified prior to therapeutic intervention with two molecules related to the pathway blocked by tocilizumab. Seminars in Arthritis and Rheumatism, 11/03/2017. (Also see Treatments for Rheumatoid Arthritis and Interleukins)
This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.

Autoantibodies (AAbs) against interleukin-21 correlate with disease activity in patients with rheumatoid arthritis (RA).
The levels of AAbs against IL-21 correlate with disease activity, which suggests that anti–IL-21 AAbs may play a role in the pathogenesis of RA. PubMed, Clin Rheumatol, 10/10/2017. (Also see Interleukins and Causes of Rheumatoid Arthritis)
This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.

Association of interleukin 13 gene polymorphisms and plasma IL 13 level with risk of systemic lupus erythematosus (SLE).
The concentration of IL-13 was significantly elevated in rs20541 CT/TT genotypes compared with CC genotype which suggests that rs20541 CT/TT genotypes may be a risk factor for SLE. PubMed, Cytokine, 10/07/2017. (Also see Causes of Lupus and Interleukins)
This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.

Interleukin-20 is triggered by toll–like receptor ligands (TLR) and associates with disease activity in patients with rheumatoid arthritis (RA).
Our data showed that IL-20 is independently associated with RA disease activity and may be triggered by TLR ligands at local sites of inflammation. PubMed, Cytokine, 2017 Sep;97:187-192. (Also see Causes of Rheumatoid Arthritis and Interleukins)
This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.

The role and therapeutic targeting of IL-6 in rheumatoid arthritis (RA).
The prospects for future applications, new therapeutic strategies of IL-6 targeting therapy and relevant issues with regard to the clinical management of IL-6 blockade in RA are discussed. PubMed, Expert Rev Clin Immunol, 2017 Jun;13(6):535-551. (Also see Causes of Rheumatoid Arthritis and Interleukins)
This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.

IL-25 blockade inhibits metastasis in breast cancer.
Inhibition of IL-25 resulted in decreased type 2 T cells and macrophages in the primary tumor microenvironments, both reported to enhance breast tumor invasion and subsequent metastasis to the lung. PubMed, Protein Cell, 2017 Mar;8(3):191-201. (Also see Cancer) and Interleukins)
This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.

Y-27632, a Rho–associated protein kinase inhibitor, inhibits systemic lupus erythematosus.
The findings showed that the inhibition of rho-associated, coiled–coil–containing protein kinase 1(ROCK) was beneficial for the prevention of systemic lupus erythematosus, which possibly by suppressing NF-κB activation. PubMed, Biomed Pharmacother, 2017 Apr;88:359-366. (Also see Interleukins and Research on Systemic Lupus Erythematosus)
This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.

Serum 25–OH vitamin D level in treatment–naïve systemic lupus erythematosus (SLE) patients: Relation to disease activity, IL-23 and IL-17.
Hypovitaminosis D contributes to ANA antibody production and is associated with high serum levels of IL-23 and IL-17 and may trigger the inflammatory process in SLE. Lupus, 12/07/2016. (Also see Research on Systemic Lupus Erythematosus and Interleukins)
This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.